Key Drivers
- Net Cash
- Cash Conversion
- Margin Pressure
AIAI Summary
RGEN is now a re-rating story, not just a steady bioprocessing grower: the BioLife acquisition and Q2 momentum could unlock higher recurring revenue and cell-therapy exposure, but the stock only works if management executes clean integration and converts growth into better margins before rich valuation and integration risk trigger disappointment.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Net Cash
- •Cash Conversion
- •Margin Pressure
RGEN has a strong net-cash balance sheet and solid cash generation, but modest profitability and heavy intangible assets leave the stock expensive at current multiples.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Resistance test
- •Pullback risk
Over the last month, RGEN reversed from a sharp selloff into a strong uptrend, but its rapid climb to near $167.49 now puts it at near-term resistance with support at $158.59-$159.44 and deeper support at $149.78.
Sharp rally from $131.06 to $166.83 signals stretched near-term momentum and pullback risk
Sentiment & News
Key News Insights:
- •Acquisition scale
- •Earnings beat
- •Legal scrutiny
Repligen strengthened its growth outlook with a $1.5B BioLife acquisition and a Q2 beat-and-raise, though the deal is facing legal scrutiny. #M&A
The stock's near-term sentiment is likely positive on stronger fundamentals and strategic expansion, but transaction-related legal risk may cap upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings